A messenger RNA (mRNA) vaccine designed to prevent human cytomegalovirus (CMV) elicited long-lasting CMV-specific responses from several types of immune cells, outperforming a previous vaccine concept in multiple measures in a NIAID-supported laboratory study. The findings were published in the Journal of Infectious Diseases.
In people with a form of lupus called systemic lupus erythematosus (SLE), the risk for a severe flare-up of disease was low for both individuals who tapered off long-term immunosuppressive therapy and those who remained on it, a clinical trial has found. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored and funded the trial. The findings were reported today in the journal The Lancet Rheumatology.
The route a pathogen takes in causing infection can determine the severity of disease. NIAID scientists are looking at metabolism to determine how and why there is a difference.
Do you know some people who almost never get sick and bounce back quickly when they do, while other people frequently suffer from one illness or another? NIAID-supported researchers have pinpointed an attribute of the immune system called immune resilience that helps explain why some people live longer and healthier lives than others.
Developing a universal influenza vaccine is a significant priority for NIAID scientists. Two new studies describe a unique candidate developed by NIAID's Vaccine Research Center that performed well in a Phase 1 clinical trial.
The study found that infants who were not infected with RSV in the first year of life had a 26% lower risk of asthma at 5 years of age than those who were infected with RSV as infants.
A team of NIAID-led researchers has identified a mechanism in mice in which the immune system and commensal bacteria help repair damaged sensory neurons within the skin. They hope their findings could lead to therapies that stimulate recovery in people following skin injury and limit damage from chemotherapy and chronic diseases.
Two recently published studies explain why some people respond better to vaccines than others and could guide the development of new strategies to enhance the antibody response to vaccination.
The first Food and Drug Administration approval of a treatment for eosinophilic esophagitis, announced in May 2022, marked a vital achievement not only for people with the disease, but also for scientists including a NIAID grantee whose research helped lay a foundation for this milestone.
The National Institutes of Health has awarded approximately $34 million annually over the next five years to fund six independent Centers for HIV Structural Biology
The national EV-D68 pilot study is part of PREMISE, the Pandemic Response Repository through Microbial and Immune Surveillance and Epidemiology. PREMISE is an initiative from NIAID’S Vaccine Research Center (VRC) that began in early 2021.
NIH Scientists Advance Understanding of Pediatric Immune Responses to COVID-19 and Rare Inflammatory Syndrome
A comprehensive analysis evaluating immune responses in children with SARS-CoV-2 infection and in those with a rare post-infection inflammatory syndrome called MIS-C has revealed distinct immunopathological signatures associated with each condition.